Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ok Muck but next time please limit yourself to 25 boxes of your finest AffiDX and make it snappy!
Forgot to mention, they confirmed that Healgen was in stock.
So, they have stock of a product they could sell now but instead preferred to promote a product they haven't got for another 2 weeks.
@sangijuelas1, understood! Should probably have mentioned I ordered 25 boxes for my business.
Not to mention ****ing with the poor sales guys conversion rate of calls to sales
Nice Muck but every time we waste their time contacting them we could be stopping an actual customer from speaking to them.
So while it might help you to steady your nerves you might actually be contributing to the losz of sales
For info, I called Bioserv playing the ignorant today, just to ask them which antigen test from their suite they would recommend.
Straightaway they launched into a spiel about Avacta, that it detects variants, and that its the most accurate they have. They pushed the fact that its UK made/developed and confirmed that their initial stock went with a next delivery in two weeks time.
The only other test they talked about was Healgen. They differentiated it by saying that its been approved for longer, and is available for self test (so no professional needed), but then talked it down by confirming its made in China and doesn't have the same accuracy as affidx.
They explained that Affidx is only available in boxes of 25 but you can order single Healgen tests. No discount unless you order more than 100 boxes.
They finished by very clearly promoting affidx as the one they would go for.
All sounds good - seems to me that we are having no problem selling and that if we were we would make the test available in smaller boxes and get a discount at lower purchase volumes.
Sujood says it's close, good enough for me...
My conclusion, for what it's worth, is that alot is hanging on Medusa19 achieving self test for AffiDx. When that drops my feeling is there will be a cascade of communications. But it has been a loooong wait. GLA.
@Timster, from avacta, I made an enquiry regarding a purchase via the contact form. No further details though. I did expect larger orders to be fulfilled direct but wasn’t sure what the threshold was to go via distributor.
Thanks Neutronic.....it was a poor attempt at sarcasm.
Roundhowe
If HMG or any gov wants our test on mass, Avacta themselves will deal with it directly, not via Bioserv.
Just for info, Bioserv are dealing with smaller orders
@stodge where did you get that 11k number from?
Avacta are directly selling palettes of 11,000 tests to organisations, any smaller numbers selling via distributor.
Wyndrum,
If it was me, Id probably want to see what demand is once the initial orders have completed.
Some of these orders will be for interested PI's. . Once they have a box or 2, will they order the next month?
So, the second run, and demand will be an interesting metric and would give more viablity to the actual quantities sold without the pent up demand built in.
I for one, would prefer a reasonable estimate over a longer period, not an initial order inflated number, which would then be priced in as a given for a set period of demand.
Give them time to clear back log, get a reasonable understanding of the market and production to match. This will even out and deliveries will be quicker.
No point making millions and not selling them, but also not making enough is damaging too. Hard to work out on first orders.
simple answer, answered by Sir Al himself many many months ago.
Supply is the problem, not demand.
Could AVCT do a better job now of informing the market about sales?
It goes on sale in Mid July but no shipments for 2 weeks. As shipments start its immediately sold out with another 2 week delay for further shipments.
If the market knew what the original run was then we can all get an accurate gauge of the numbers involved. Why this is not published seems odd to me. Why the secrecy? This can't be anything to do with NDA's
What capacity is available? Is it a million a week or less or more? No shipments for another 2 weeks so why is not production either being ramped up or at least drip fed to Calibre, say 100,000 tests or 50,000 per day or whatever?
On the face of it this is extremely encouraging. Given the SP turmoil of recent weeks this would seem to be a great opportunity to reassure investors.
AVCT don't make it easy, that's for sure
Certainly is, place an order, simples
I think Bioserv are just the UK arm of Calibre, who operate out of six countries and cover 100 countries for delivery.
Don't think all production is going to Bioserv in the UK.
Onwards Avacta.
Don't know Timster.
I have replied again to the email to try to get a better understanding of the supply coming into Bioserve from Avacta. Doubt I will get the answers I am looking for. But we shall see.
Seems odd though we supposedly have 2 million capacity, would they really sell all that through bioserve or are they just allocated a small percentage and the rest set aside for the large contracts that are soon to be announced...
Thanks Runner. A little more meat on the bones. A positive development.
Yes.
I made some enquiries at the weekend to Bioserve to try to guage the reliability of ongoing supply of Affidx from manufacturer to distributor. Had the following reply this am.
"We received a large shipment from Avacta on Friday. However, all these kits have been allocated unfortunately. We will be receiving the next shipment in 2 weeks from Avacta. ETA is 16 August. Would you like to place an order for Avacta kits?"
So. On the one hand, good that they have sold all of the first shipment. But now currently out of stock for the next 2 weeks.
Sounds right.
I ask because the twitter reference (I usually take twitter with a punch of salt) suggested current stock all spoken for, next delivery 16 Aug. Wondered if they had alluded to that when taking your order . . . as a way of verifying the twitter post.
Thanks.
Unfortunately not. I suppose they could still be allowing orders with a view to filling them when they receive more stock.
123jez,
Did they give you a delivery date?
Thanks
Remember "Avacta will continue to focus on developing direct sales opportunities to major corporates and other large scale end users." perhaps other orders need to be filled .
""We are delighted that we have put in place this distribution agreement for the AffiDX SARS-CoV-2 antigen lateral flow test for professional use with Calibre. As a high quality, global distributor of diagnostics and life science products with excellent links to our target markets, we are confident Calibre is well placed to support our penetration of the professional end use market in the UK and EEA.
"Avacta will continue to focus on developing direct sales opportunities to major corporates and other large scale end users.